A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript

PURPOSE: In a preclinical drug screen, mithramycin was identified as a potent inhibitor of the Ewing sarcoma EWS–FLI1 transcription factor. We conducted a phase I/II trial to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of mithramycin in child...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Chemother Pharmacol
Autori principali: Grohar, Patrick J., Glod, John, Peer, Cody J., Sissung, Tristan M., Arnaldez, Fernanda I., Long, Lauren, Figg, William D., Whitcomb, Patricia, Helman, Lee J., Widemann, Brigitte C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6413860/
https://ncbi.nlm.nih.gov/pubmed/28735378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3382-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi